Completed PHASE4 INTERVENTIONAL 3-arm NCT02246712

Influence of Diabetes on Tramadol Pharmacokinetics

Influence of Uncontrolled Diabetes on the Kinetic Disposition, Metabolism and Pharmacokinetics-pharmacodynamics of Tramadol Enantiomers in Patients With Neuropathic Pain

Sponsor: Universidade Estadual Paulista Júlio de Mesquita Filho

Conditions Neuropathic Pain Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus

Interventions CYP2B6 genotype CYP2D6 phenotype CYP3A phenotype Single oral dose of 100 mg racemic tramadol

Updated 5 times since 2017 Last updated: Sep 18, 2014 Started: Jun 30, 2008 Primary completion: May 31, 2010 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Neuropathic Pain and Type 1 Diabetes Mellitus and is currently completed. Universidade Estadual Paulista Júlio de Mesquita Filho leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universidade Estadual Paulista Júlio de Mesquita Filho
University of Sao Paulo

Data source: Universidade Estadual Paulista Júlio de Mesquita Filho

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Araraquara, Brazil